Two Covid-19 antibody treatments from different companies combined in new study

Study to combine two Covid-19 antibody treatments from different companies. Picture: Andy Buchanan/PA

A new clinical study is being launched to see whether two Covid-19 antibody treatments made by different pharmaceutical companies can be combined to improve patient outcomes.

British drugs firm GlaxoSmithKline (GSK) and clinical-stage immunology company Vir Biotechnology’s treatment, known as VIR-7831, will be given to low-risk patients with mild to moderate Covid-19 alongside bamlanivimab, developed by US pharmaceutical company Lilly.